The pulmonary route as a way to drug repositioning in COVID-19 therapy

Detalhes bibliográficos
Autor(a) principal: Sarcinelli, MIchelle Alvares
Data de Publicação: 2021
Outros Autores: Silva, Thalita Martins da, Silva, Andressa Daniele Artico, Patricio, Beatriz Ferreira de Carvalho, Paiva, Flávia Costa Mendes de, Lima, Raissa Santos de, Silva, Manuela Leal da, Rocha, Helvécio Vinícius Antunes
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/53868
Resumo: Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
id CRUZ_2efa4c741427942c740e2d8d68990ca4
oai_identifier_str oai:www.arca.fiocruz.br:icict/53868
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Sarcinelli, MIchelle AlvaresSilva, Thalita Martins daSilva, Andressa Daniele ArticoPatricio, Beatriz Ferreira de CarvalhoPaiva, Flávia Costa Mendes deLima, Raissa Santos deSilva, Manuela Leal daRocha, Helvécio Vinícius Antunes2022-07-19T17:14:25Z2022-07-19T17:14:25Z2021SARCINELLI, Michelle Alvares et al. The pulmonary route as a way to drug repositioning in COVID-19 therapy. Journal of Drug Delivery Science and Technology , v. 63, 102430, p. 1-15, Feb. 2021.1773-2247https://www.arca.fiocruz.br/handle/icict/5386810.1016/j.jddst.2021.102430Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Famanguinhos. Programa de Pós-graduação em Pesquisa Translacional em Fármacos e Medicamentos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Famanguinhos. Programa de Pós-graduação em Pesquisa Translacional em Fármacos e Medicamentos. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa de Pós-Graduação em Biologia Computacional e Sistemas,. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Programa de Pós-Graduação em Biologia Computacional e Sistemas,. Rio de Janeiro, RJ, Brasil / Universidade Federal Do Rio de Janeiro. Instituto de Biodiversidade e Sustentabilidade (NUPEM), Macaé, RJ, Brasil.Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Laboratório de Micro e Nanotecnologia. Rio de Janeiro, RJ, Brasil / Rede Rio de Inovação em Nanossistemas para a Saúde. NanoSAÚDE/FAPERJ. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto de Tecnologia em Fármacos. Famanguinhos. Programa de Pós-graduação em Pesquisa Translacional em Fármacos e Medicamentos. Rio de Janeiro, RJ, Brasil.Introduction: The outbreak of the disease caused by the new coronavirus (COVID-19) has been affecting society’s routine and its patterns of interaction worldwide, in addition to the impact on the global economy. To date, there is still no clinically effective treatment for this comorbidity, and drug repositioning might be a good strategy considering the established clinical safety profile. In this context, since COVID-19 affects the respiratory tract, a promising approach would be the pulmonary drug delivery. Objective: Identify repurposing drug candidates for the treatment of COVID-19 based on the data of ongoing clinical trials and in silico studies and also assess their potential to be applied in formulations for pulmonary administration. Method: A integrative literature review was conducted between June and July 2020, by extracting the results from Clinical Trials, PubMed, Web of Science and Science Direct databases. Results: By crossing the results obtained from diverse sources, 21 common drugs were found, from which only 4 drugs presented studies of pulmonary release formulations, demonstrating the need for greater investment and incentive in this field. Conclusion: Even though the lung is a target that facilitates viral infection and replication, formulations for pulmonary delivery of suitable drugs are still lacking for COVID-19 treatment. However, it is indisputable that the pandemic constitutes a concrete demand, with a profound impact on public health, and that, with the appropriate investments, it will give the pharmaceutical industry an opportunity to reinforce the pulmonary delivery field.engElsevierSARS-CoV-2CoronavírusFormulações pulmonaresAdministração de drogas pulmonaresReaproveitamento de drogasSARS-CoV-2CoronavirusPulmonary formulationsPulmonary drug deliveryDrug repurposingThe pulmonary route as a way to drug repositioning in COVID-19 therapyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/53868/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALRaissaLima_ManuelaLealSilva_etal_IOC_2021.pdfRaissaLima_ManuelaLealSilva_etal_IOC_2021.pdfapplication/pdf3299719https://www.arca.fiocruz.br/bitstream/icict/53868/2/RaissaLima_ManuelaLealSilva_etal_IOC_2021.pdfa9b0e4a17967cd85e58e18461b109ab3MD52icict/538682022-11-20 12:27:56.913oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-11-20T15:27:56Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv The pulmonary route as a way to drug repositioning in COVID-19 therapy
title The pulmonary route as a way to drug repositioning in COVID-19 therapy
spellingShingle The pulmonary route as a way to drug repositioning in COVID-19 therapy
Sarcinelli, MIchelle Alvares
SARS-CoV-2
Coronavírus
Formulações pulmonares
Administração de drogas pulmonares
Reaproveitamento de drogas
SARS-CoV-2
Coronavirus
Pulmonary formulations
Pulmonary drug delivery
Drug repurposing
title_short The pulmonary route as a way to drug repositioning in COVID-19 therapy
title_full The pulmonary route as a way to drug repositioning in COVID-19 therapy
title_fullStr The pulmonary route as a way to drug repositioning in COVID-19 therapy
title_full_unstemmed The pulmonary route as a way to drug repositioning in COVID-19 therapy
title_sort The pulmonary route as a way to drug repositioning in COVID-19 therapy
author Sarcinelli, MIchelle Alvares
author_facet Sarcinelli, MIchelle Alvares
Silva, Thalita Martins da
Silva, Andressa Daniele Artico
Patricio, Beatriz Ferreira de Carvalho
Paiva, Flávia Costa Mendes de
Lima, Raissa Santos de
Silva, Manuela Leal da
Rocha, Helvécio Vinícius Antunes
author_role author
author2 Silva, Thalita Martins da
Silva, Andressa Daniele Artico
Patricio, Beatriz Ferreira de Carvalho
Paiva, Flávia Costa Mendes de
Lima, Raissa Santos de
Silva, Manuela Leal da
Rocha, Helvécio Vinícius Antunes
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Sarcinelli, MIchelle Alvares
Silva, Thalita Martins da
Silva, Andressa Daniele Artico
Patricio, Beatriz Ferreira de Carvalho
Paiva, Flávia Costa Mendes de
Lima, Raissa Santos de
Silva, Manuela Leal da
Rocha, Helvécio Vinícius Antunes
dc.subject.other.pt_BR.fl_str_mv SARS-CoV-2
Coronavírus
Formulações pulmonares
Administração de drogas pulmonares
Reaproveitamento de drogas
topic SARS-CoV-2
Coronavírus
Formulações pulmonares
Administração de drogas pulmonares
Reaproveitamento de drogas
SARS-CoV-2
Coronavirus
Pulmonary formulations
Pulmonary drug delivery
Drug repurposing
dc.subject.en.pt_BR.fl_str_mv SARS-CoV-2
Coronavirus
Pulmonary formulations
Pulmonary drug delivery
Drug repurposing
description Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
publishDate 2021
dc.date.issued.fl_str_mv 2021
dc.date.accessioned.fl_str_mv 2022-07-19T17:14:25Z
dc.date.available.fl_str_mv 2022-07-19T17:14:25Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv SARCINELLI, Michelle Alvares et al. The pulmonary route as a way to drug repositioning in COVID-19 therapy. Journal of Drug Delivery Science and Technology , v. 63, 102430, p. 1-15, Feb. 2021.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/53868
dc.identifier.issn.pt_BR.fl_str_mv 1773-2247
dc.identifier.doi.none.fl_str_mv 10.1016/j.jddst.2021.102430
identifier_str_mv SARCINELLI, Michelle Alvares et al. The pulmonary route as a way to drug repositioning in COVID-19 therapy. Journal of Drug Delivery Science and Technology , v. 63, 102430, p. 1-15, Feb. 2021.
1773-2247
10.1016/j.jddst.2021.102430
url https://www.arca.fiocruz.br/handle/icict/53868
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/53868/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/53868/2/RaissaLima_ManuelaLealSilva_etal_IOC_2021.pdf
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
a9b0e4a17967cd85e58e18461b109ab3
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324810970824704

Registros relacionados